Dr. Venugopal Offers Her Thoughts on the Latest MDS News

Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease. She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.